Semivoluntary movement (=unvoluntary)
|
|
- Rachel Turner
- 5 years ago
- Views:
Transcription
1 EXTRAPYRAMIDAL DISORDERS = Movement disorders = Degenerative disease 1
2 4 types of movements: Voluntary movement Semivoluntary movement (=unvoluntary) Involuntary movement Automatic movement 2
3 3
4 Movement disorders = Extrapyramidal disorder Disorder of regulation of voluntary motoric activity without direct influence towards muscle strength, sensibility, or cerebellum. 4
5 Extrapyramidal disorder Hyperkinetic disorder: abnormal involuntary movements Hypokinetic disorder: reduction of movements. = Movement disorders are caused by dysfunction of basal ganglia 5
6 Basal ganglia: Caudate nucleus Putamen Globus pallidus Subthalamic nucleus Substantia nigra 6
7 Diseases & syndrome with abnormal movements: Essential tremor (familial / benign) Parkinsonism Progressive supranuclear palsy Idiopathic torsion dystonia Chorea sydenham Sindroma Gilles de la Tourette Drug-induced movement disorders, etc. 7
8 Parkinsonism = Parkinson syndrome 1. Primary / Idiopathic = Paralysis agitans = Parkinson disease 2. Secondary/Symptomatic = Causes: - arteriosclerosis - anoxia /cerebral ischemia - drugs - toxic agent - encephalitis etc. 8
9 Parkinsonism (CON T) 3. Paraparkinson / Parkinson plus - Wilson disease - Huntington disease - Normotensive Hydrocephalus 9
10 Parkinson disease = Parkinson idiopathic = Paralysis agitans - Most commonly be found - Middle age to old age 10
11 Etiology and pathogenesis The certain Etiology is unknown PD is due to cells degeneration dopamine decreased in substantia nigra 11
12 ACh DA I DA ACh I ACh i DA 12
13 Hypotesis: Aging process: dopaminergic neuronal death!!! anti oxydative-protective mechanism decreased Environmental toxin: - heavy metal (Iron, Zinc, mercury etc) - MPTP Genetic sensitivity Oxydative stress: dopamine reaction free radicals 13
14 Pathology Cutting of mid-brain: degeneration & neuronal death which contain melanin in substansia-nigra. Microscopic: In compacta zone: - Most of neuron are loss - Residual : containings Lewy-bodies 14
15 Lewy bodies in subst.nigra: 15
16 Clinical findings. Triad of symptoms: - rigidity - tremor - bradikinesis 1. tremor: - pill rolling tremor - during tension!!!, sleep - disappear - resting tremor = Parkinsonian tremor 16
17 Clinical findings (Con t) 2. Rigidity : cogwheel phenomenon. 3. Bradikinese 4. Weakness & fatique 5. Dystonia 6. Parkinsonian facies mask-like 7. Micrographia 8. Gait: Festinant gait = Parkinsonian gait 17
18 Clinical findings (con t) 9. freezing: late stage, suddlenly stop walking 10. Slowly speaking and monotone 11. Eye movements: - lack of blinking - eye movement disturb. - Glabella reflex (+) 12. Pain: paresthesia of limbs 18
19 Clinical findings (con t) 13. ANS disturbance: - salivary / excessive sweating -urinary incontinence etc. 14. Saliva!!! sialorrhea 15. Hypotension orthostatic hypotension 16. Depression 17. Dementia 19
20 Gait: 20
21 Tremor: 21
22 Rising: 22
23 Sitting: 23
24 Hypomimia: 24
25 Retropulsion: 25
26 Freezing: 26
27 Diagnostic procedure Diagnosis is made clinically based on clinical symptoms found EEG examination : may show diffuse slow wave MRI & CT Scan : may show cortical atrophy. 27
28 Treatment It is considered: due to dopamine deficiency in CNS. 1. Levodopa 2. Anticholinergic drugs: trihexyphenidyl 3. Antihistamine: diphenhydramine 4. Bromocriptine 5. Amantadine 6. Selegiline 28
29 TH DD L-tyrosine l-dopa DA TH: tyrosine hydroxylase DD: dopa-decarboxylase DA located outside vesicles will be catalyzed by enzymes : MAO(monoamine-oxydase) inside the neuron cell COMT(catechol-o-methyl-transferase) outside the neuron cell. 29
30 In peripheral : 1. l-dopa dopamine I dopa-decarboxylase v ^ dopa-decarboxylase inhibitor = carbidopa sinemet = benserazide madopar b 30
31 2. l-dopa dopamine I catechol-o-methyltransferase (COMT) v ^ COMT inhibitor : - tolcapone - entacapone 31
32 Prognosis: The prognosis is still poor. 32
33 Diseases & syndromes with abnormal movements : Essential tremor (familial / benign) Parkinsonism Progressive supranuclear palsy Idiopathic torsion dystonia Chorea sydenham Sindroma Gilles de la Tourette Drug-induced movement disorders, etc. 33
34 Parkinsonism = Parkinson syndrome 1. Primary/ Idiopathic = Paralysis agitans = Parkinson disease 2. Secondary / Symptomatic = Well known causes : - arteriosclerosis - anoxia / cerebral ischemia - drugs - toxic agents - encephalitis, etc. 34
35 Parkinsonism (Con t) 3. Paraparkinson / Parkinson plus - Wilson disease - Huntington disease - Normotensive Hydrocephalus 35
36 ESSENTIAL TREMOR Familial tremor Benign tremor Autosomal dominant Begin at teen-agers or young adults 36
37 Tremor usually affect one or both hands, head and voices, whereas foot is not affected. Neurological assessments show no other abnormality. Despite the longer the tremor the clearer the symptoms, usually it does not disturb,but the patient feels ashamed. 37
38 Sometimes it disturbs fine and difficult movements, writing and speaking when laryngeal muscle is involved. Consuming small amount of alcohol temporary improvement is reported, but the mechanism has not been known yet. 38
39 Treatment - Diazepam 6 15 mg per day - Propranolol mg per day - Primidone - Alprazolam - Not responsive: # thalamotomy # thalamic stimulation 39
40 CHOREA SYDENHAM Affecting children and young adults resulting from complication of streptococcus hemolytic A infection and the possible basic pathological features is arteritis. Approximately 30% of cases occur 2 or 3 months following rheumatoid fever or polyarthritis, the rest without such historys. 40
41 Onset can be acute or gradually within 4-6 months, can also occur during pregnancy or oral contraceptive users. Symptoms including abnormal chorea movements, sometimes unilaterally in mild cases. Changes of behavior In children may reveal easily to anger and doughty Labile of emotions 41
42 In 30% of cases involves the heart Treatment: bed rest, sedatives, prophylaxis antibiotics even though without acute rheumatoid fever. Penicillin injection to be continued orally until 20 years of age to prevent staphylococcal infection. The prognosis basically lies on the complication of the heart. 42
43 Drug-induced movement disorders 1. Parkinsonism 2. Acute dystonia or dyskinesis 3. Akathisia 4. Tardive dyskinesis 5. Neuroleptic malignant syndrome 6. Others. 43
44 Parkinsonism. Complication of dopamine receptor inhibitor drugs: - phenothiazine - butyrophenone - thioxanthene - metoclopramide 44
45 Parkinsonism (Con t) Symptoms : - rigidity - mask-like face - bradykinesis - tremor (seldom) Treatment : - Discontinue the drug - anti-cholinergic drugs (trihexyphenidyl) 45
46 Acute dystonia / dyskinesia blepharospasm torticollis facial grimacing following phenothiazine administration. Treatment: Intravenous anti-cholinergicdrug (benztropine 2 mg or diphenhydramine 50 mg). 46
47 Blepharospasm 47
48 Akathisia Motoric restlessness, compulsion to move or inability to sit still for more than a short period of time, keep standing or walking. Receiving phenothiazine Treatment: - Lowering the dose if possible - propranolol mg/hari - anticholinergic drugs / benzodiazepines 48
49 Tardive dyskinesia Repetitive involuntary movements of the mouth, tongue and lips, occasionally accompanied by dystonic posturing or choreoathetotic movements of trunk and limbs. Mostly following administration of neurolep tic, metoclopramide, antihistamines, tricyclic antidepressant and chronic alcohol abuse. 49
50 50
51 Tardive dyskinesia (Con t) Treatment: - Dopamine antagonists : haloperidol - Catecholamine-depleting agents: reserpine, tetrabenazine. - Baclofen - Calcium channel blocking agents - Vitamin E, etc. 51
52 Neuroleptic malignant syndrome An acute idiosyncratic reaction to - neuroleptic medication due to central dopamine receptor blockade. May also originate from non-neurololeptic drugs: metoclopramide, domperidone, amphetamines, reserpine, tetrabenazine, tricyclic antidepressants with lithium or with MAO inhibitor and withdrawal of antiparkinsonian medication. 52
53 Neuroleptic malignant syndrome(con t) The use of cocaine and 3.4 methy- lene dioxymethamphetamine (MDMA) = Ecstasy Symptoms are usually abrupt in onset, fever, encephalopathy with fluctuating confusion and agitation progressing to coma, labile BP, tachycardia, diaphoresis in association with dystonia and tremor. The couse is often rapid in untreated cases wit deterioration leading to cardiac failure, pulmonary congestion, pneumonia, renal failure and death. 53
54 Neuroleptic malignant syndrome (Con t) Treatment: - Discontinue the neuroleptic drugs - Control of body temperature - Monitor the BP, urine, electrolytes, temperature change - Administer bromocriptine mg/day by NGT - Dantrolene sodium i.v and convert to oral as improvement occurs. 54
55 Others: Levodopa various abnormal movement is related to dosage. Bromocriptine, anticholinergic drugs, phenytoin, carbamazepine, amphetamine, lithium and oral contraceptive may also result in chorea ect. 55
Parkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationProfessor Tim Anderson
Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationMovement Disorders. Eric Kraus, MD! Neurology!
Movement Disorders Eric Kraus, MD! Neurology! Classify Bradykinesia! Tic! Myoclonus! Tremor! Dystonia! Athetosis! Chorea! Ballismus! Case 1 This 64 year-old female has had progression of a tremor over
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationParts of the motor circuits
MOVEMENT DISORDERS Parts of the motor circuits cortical centers: there are centers in all the cortical lobes subcortical centers: caudate nucleus putamen pallidum subthalamical nucleus (Luys) nucleus ruber
More informationBasal ganglia Sujata Sofat, class of 2009
Basal ganglia Sujata Sofat, class of 2009 Basal ganglia Objectives Describe the function of the Basal Ganglia in movement Define the BG components and their locations Describe the motor loop of the BG
More informationIdentification number: TÁMOP /1/A
Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master s Programmes at the University of Pécs and at the University of Debrecen Identification
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationParkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.
Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Four (4) hallmark clinical signs: 1) Tremor: (Note -
More informationExtrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010
Extrapyramidal Motor System Basal Ganglia or Striatum Descending extrapyramidal paths receive input from other parts of motor system: From the cerebellum From the basal ganglia or corpus striatum Caudate
More informationMartin A. Samuels, M.D. MOVEMENT DISORDERS
Martin A. Samuels, M.D. MOVEMENT DISORDERS I. Nomenclature of Movement Disorders A. Too Little Movement 1. Paralysis (paresis) 2. Rigidity a. spasticity (pyramidal) b. "lead pipe" (extra pyramidal) c.
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationProfessor Tim Anderson
Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition
More informationParkinson's Disease. Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology
Parkinson's Disease Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology 18 February 2002 Parkinson Disease Neurological disease affecting over four million patients
More informationMargo J Nell Dept Pharmacology
Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More information475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)
475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationA. General features of the basal ganglia, one of our 3 major motor control centers:
Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. April 22, 2010 THE BASAL GANGLIA Objectives: 1. What are the
More informationThe motor regulator. 1) Basal ganglia/nucleus
The motor regulator 1) Basal ganglia/nucleus Neural structures involved in the control of movement Basal Ganglia - Components of the basal ganglia - Function of the basal ganglia - Connection and circuits
More informationA. General features of the basal ganglia, one of our 3 major motor control centers:
Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. March 1, 2012 THE BASAL GANGLIA Objectives: 1. What are the main
More informationVL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements
BASAL GANGLIA Chris Cohan, Ph.D. Dept. of Pathology/Anat Sci University at Buffalo I) Overview How do Basal Ganglia affect movement Basal ganglia enhance cortical motor activity and facilitate movement.
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationDisorders of Movement M A R T I N H A R L E Y N E U R O L O G Y
Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y Educational Objectives Improved history taking in patients with movement disorders. Develop a systematic approach to observing and describing
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationmovement disorders for psychiatrists
Movement disorders for psychiatrists Nandakumar Narayanan Assistant Professor, Neurology University of Iowa Thanks to Dr. Rodnitkzy Funding for my lab National Institutes of Health Carver Medical Trust
More informationANTIPARKINSONIAN DRUGS. DRUGs ACT ON CNS (Pharmacology) Unit-5(8)
ANTIPARKINSONIAN DRUGS DRUGs ACT ON CNS (Pharmacology) Unit-5(8) Parkinsonism (PD) Extrapyramidal motor function disorder characterized by Rigidity Tremor Hypokinesia/Bradykinesia Impairment of postural
More informationMovement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types
Background Movement Disorders Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Early Studies Found some patients with progressive weakness
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationParkinson s Disease. Patients will ask you. 8/14/2015. Objectives
Parkinson s Disease Jean Van Kingsley MS, FNP-BC Objectives Describe the pathophysiolgy of PD. Review clinical charachteristics of PD. Identify management strategies, to maximize functional status. Recognize
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationChapter 161 Antipsychotics
Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in
More information8/28/2017. Behind the Scenes of Parkinson s Disease
BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationDIFFERENTIAL DIAGNOSIS SARAH MARRINAN
Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE
ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging Dr. Olav E. Krigolson krigolson@uvic.ca Lecture 5: PARKINSONS DISEASE The Basal Ganglia Primary motor cortex Execution of movement
More informationNeurodegenerative diseases
Neurodegenerative diseases Hiwa K. Saaed, PhD Department of Pharmacology & Toxicology College of Pharmacy University of Sulaimani Hiwa.saaed@univsul.edu.iq 2018-19 Neurodegenerative diseases of the CNS
More informationCOALINGA STATE HOSPITAL. Effective Date: August 31, 2006
COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION Emergency Procedures POLICY NUMBER: 717 Effective Date: August 31, 2006 SUBJECT: NEUROLEPTIC MALIGNANT SYNDROME 1. PURPOSE: To provide
More informationDepartment of Neurology, Rigshospitalet, 9 Blegdamsvej, PAULSON, O.B. Involuntary Movements. Tohoku J. Exp. Med., 1990, 161,
Tohoku J. Exp. Med., 1990, 161, Suppl., 21-27 Involuntary Movements OLAF B. PAULSON Department of Neurology, Rigshospitalet, 9 Blegdamsvej, DK-2100, Copenhagen, Denmark PAULSON, O.B. Involuntary Movements.
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationInvoluntary Movements in Children and Adolescents: Is it Seizure, Tic or Something Else?
Involuntary Movements in Children and Adolescents: Is it Seizure, Tic or Something Else? California Association of Nurse Practitioners Monterey, March 22, 2013 Julie Sprague-McRae, MS, RN, PPCNP-BC Ruth
More informationAn approach to movement disorders. Kailash Bhatia, DM, FRCP Professor of Clinical Neurology Institute of Neurology Queen Square, London
An approach to movement disorders Kailash Bhatia, DM, FRCP Professor of Clinical Neurology Institute of Neurology Queen Square, London Neurology Diagnosis Two main questions: What parts of the nervous
More informationDifferential Diagnosis of Hypokinetic Movement Disorders
Differential Diagnosis of Hypokinetic Movement Disorders Dr Donald Grosset Consultant Neurologist - Honorary Professor Institute of Neurological Sciences - Glasgow University Hypokinetic Parkinson's Disease
More informationParkinson s Disease Update
Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms
More informationStrick Lecture 4 March 29, 2006 Page 1
Strick Lecture 4 March 29, 2006 Page 1 Basal Ganglia OUTLINE- I. Structures included in the basal ganglia II. III. IV. Skeleton diagram of Basal Ganglia Loops with cortex Similarity with Cerebellar Loops
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationExtrapyramidal Symptoms Associated with Antipsychotic Use
Extrapyramidal Symptoms Associated with Antipsychotic Use Tamara Pringsheim, MD, FRCPC, FAAN Associate Professor, University of Calgary Department of Clinical Neurosciences, Psychiatry, Pediatrics and
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationParkinson s Disease and Its Treatment
Parkinson s Disease and Its Treatment By H. David Bergman, Ph.D. Dean, Southwestern Oklahoma State University, College of Pharmacy Goals and Objectives Goals: To provide the pharmacist with information
More informationMOVEMENT OUTLINE. The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement
MOVEMENT 2 Dr. Steinmetz 3 OUTLINE The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement Parkinson s Disease Huntington s Disease 1 4 TYPES
More informationDISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a
More informationDrugs Affecting the Central Nervous System
Asst Prof Inam S Arif isamalhaj@yahoo.com Drugs Affecting the Central Nervous System Ass Efferent neurons in ANS Neurodegenerative Diseases Parkinson s Disease Multiple Sclerosis Alzheimer s Disease
More informationBasal Ganglia. Today s lecture is about Basal Ganglia and it covers:
Basal Ganglia Motor system is complex interaction between Lower motor neurons (spinal cord and brainstem circuits) and Upper motor neurons (pyramidal and extrapyramidal tracts) plus two main regulators
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationAlison Charleston 1 st September 2016
Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence
More informationMarch 2004 Parkinson s Disease H01
W-F Professional Associates, Inc. 400 Lake Cook Rd., Suite 207 Deerfield, IL 60015 847-945-8050 March 2004 Parkinson s Disease 707-000-04-003-H01 FLORIDA PHARMACISTS READ THIS VERY IMPORTANT CE BROKER
More informationMOVEMENT DISORDERS UPDATE H. MURRAY TODD, M.D., F.A.A.N.
MOVEMENT DISORDERS UPDATE H. MURRAY TODD, M.D., F.A.A.N. Movement Disorders Hypokinesia : decreased voluntary and automatic movements Hyperkinesia : excessive movements HYPOKINESIAS Parkinson s disease
More informationClinical Features and Treatment of Parkinson s Disease
Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationDrug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)
Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl
More informationTremor 101. Objectives 9/30/2015. Importance of tremors
Tremor 101 Umer Akbar, MD Assistant Professor, Brown University Movement Disorders Program, Rhode Island Hospital & Butler Hospital Objectives Recognize and describe the qualities of common types of tremor
More informationM. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment
M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz Parkinson s Disease A Guide to Medical Treatment SEEd srl. All rights reserved Piazza Carlo Emanuele II, 19 10123 Torino, Italy Tel. 011.566.02.58
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationLecture 5 Skeletal muscle relaxants. Pharmacologic management of parkinsonism and other movement disorders.
Lecture 5 Skeletal muscle relaxants. Pharmacologic management of parkinsonism and other movement disorders. I. SKELETAL MUSCLE RELAXANTS Skeletal muscle relaxants are pharmacologically active substances
More informationMovement disorders. Dr Rick Leventer Royal Children s Hospital
Movement disorders Dr Rick Leventer Royal Children s Hospital richard.leventer@rch.org.au Movement disorders! conditions that affect the speed, fluency, quality, and ease of movement! usually affect TONE
More informationParkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationDamage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms.
Lecture 20 - Basal Ganglia Basal Ganglia (Nolte 5 th Ed pp 464) Damage to the basal ganglia produces involuntary movements. Although the basal ganglia do not influence LMN directly (to cause this involuntary
More informationVisualization and simulated animations of pathology and symptoms of Parkinson s disease
Visualization and simulated animations of pathology and symptoms of Parkinson s disease Prof. Yifan HAN Email: bctycan@ust.hk 1. Introduction 2. Biochemistry of Parkinson s disease 3. Course Design 4.
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationFirst described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"
Parkinson's Disease First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy" Parkinson s disease (PD) is a neurological disorder characterized by a progressive
More informationAn Approach to Patients with Movement Disorders
An Approach to Patients with Movement Disorders Joaquim Ferreira, MD, PhD Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon EDUCATIONAL TOOLS MDS video library
More information2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).
Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationChapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.
Chapter 8 Parkinsonism M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Definition of Parkinson s Disease Parkinson's disease is a progressive, neurodegenerative disease
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Parkinson s disease affects individuals globally (WHO 2006). It is the most common serious movement disorder, including speech
More informationChapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis
Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationObjectives. Distinguishing Parkinson s disease from other parkinsonian and tremor syndromes. Characteristics. Basal Ganglia Structures
12:45 1:30 pm PD or not PD? Distinguishing Parkinson s Disease From Other Parkinsonian and Tremor Syndromes SPEAKER Jennifer G. Goldman, MD, MS Presenter Disclosure Information The following relationships
More informationFunctional Distinctions
Functional Distinctions FUNCTION COMPONENT DEFICITS Start Basal Ganglia Spontaneous Movements Move UMN/LMN Cerebral Cortex Brainstem, Spinal cord Roots/peripheral nerves Plan Cerebellum Ataxia Adjust Cerebellum
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationParkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease Initial Clinical and Diagnostic Evaluation J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported
More informationSign up to receive ATOTW weekly -
PARKINSON S DISEASE ANAESTHESIA TUTORIAL OF THE WEEK 45 1 st FEBRUARY 2007 Dr Ritu Gupta ritugupta@doctors.org.uk MCQ s 1. During anaesthesia, a patient with Parkinson s disease on levodopa should not
More informationHyperkinetic movement disorders are. Hyperkinetic Movement Disorders. Cases in Movement Disorders. James case. About Tom
Hyperkinetic Movement Disorders Sarah Furtado, MD, PhD, FRCPC James case A mother brings her son James, 10, to your office because of repetitive sniffing sounds and repetitive eye blinking. This sniffing
More informationSTEADY YOUR APPROACH TO TREMOR (OVERVIEW OF DIFFERENTIAL DIAGNOSIS)
STEADY YOUR APPROACH TO TREMOR (OVERVIEW OF DIFFERENTIAL DIAGNOSIS) Karen M. Thomas D.O. Diplomate, ABPN Director of Movement Disorders Program Director of Comprehensive Parkinson s Disease Program Sentara
More informationThe symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:
1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing
More informationDystonia: Title. A real pain in the neck. in All the Wrong Places
Focus on CME at the University of Western Ontario Dystonia: Title in All the Wrong Places A real pain in the neck By Mandar Jog, MD, FRCPC and; Mary Jenkins, MD, FRCPC What is dystonia? Dystonia is a neurologic
More informationUNIVERSITY OF JORDAN FACULTY OF MEDICINE DEPARTMENT OF PHYSIOLOGY & BIOCHEMISTRY NEUROPHYSIOLOGY (MEDICAL) Spring, 2014
UNIVERSITY OF JORDAN FACULTY OF MEDICINE DEPARTMENT OF PHYSIOLOGY & BIOCHEMISTRY NEUROPHYSIOLOGY (MEDICAL) Spring, 2014 Textbook of Medical Physiology by: Guyton & Hall, 11 th edition 2006 Eman Al-Khateeb,
More information